Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Clinical Immunology · Activated PI3K-delta syndrome type 1

Understanding Your APDS1 Diagnosis

At a Glance

APDS1 is a rare PIK3CD-related immune disorder that causes both weak protection against infections and harmful immune overactivity. Diagnosis usually depends on a pathogenic or likely pathogenic PIK3CD variant, while symptoms and severity vary among people.

Receiving a diagnosis of Activated PI3K Delta Syndrome type 1 (APDS1) often brings a complicated mix of relief and overwhelm. For many families, this name is the end of a long, frustrating search for answers—a “diagnostic odyssey” that can span years of unexplained illness. Because APDS1 is an ultra-rare condition, affecting approximately 1 to 2 people per million, most local doctors have never encountered it [1][2]. This page will help you understand what this diagnosis means, why it took so long to find, and how it uniquely affects the body.

The Diagnostic Journey: A Long Road to Answers

It is common for there to be a significant gap between when symptoms first appear and when a formal diagnosis of APDS1 is made. While symptoms often begin in early childhood—frequently around age 2—the path to a correct diagnosis is rarely straight [3][4].

  • Age of Onset: Most patients begin experiencing recurrent infections or other symptoms at a median age of about 15 to 18 months [3][5].
  • The Diagnostic Delay: Research shows a wide range in how long it takes to get an answer, though this is changing with broader genomic testing. In some older cohorts, the median delay was reported as nearly 13 years [3]. Other smaller studies have found a shorter gap of about 4 years, but the reality for many was a decade or more of searching [5].
  • The “Invisible” Nature: Because the initial symptoms (like ear infections or sinus trouble) look like common childhood illnesses, many doctors may not realize they are seeing a rare genetic condition until the infections become frequent or lead to permanent changes like lung scarring.

The Dual Nature of APDS1

APDS1 is unique because it causes the immune system to be “broken” in two different ways at the same time. This is caused by a variation in the PIK3CD gene, which provides instructions for a protein that acts like a “gas pedal” for white blood cell growth [6]. In APDS1, this pedal is stuck down, leading to two conflicting problems:

1. Immune Deficiency (The “Underactive” Side)

The “stuck” gas pedal can impair your immune cells from maturing properly. They are so busy signaling and dividing that they often fail to effectively fight off germs [7]. This leads to:

  • Recurrent Infections: Frequent bouts of pneumonia, ear infections (otitis media), and sinus infections (sinusitis) [8].
  • Low Antibody Levels: Many patients have low levels of IgG or IgA (protective proteins in the blood), making it harder for the body to remember and fight off viruses or bacteria [9].

2. Immune Dysregulation (The “Overactive” Side)

While the immune system is failing to protect you from outside germs, it is simultaneously working too hard in ways that can hurt the body. This is known as immune dysregulation [4].

  • Lymphoproliferation: This is the medical term for the overgrowth of immune cells, which causes the lymph nodes, spleen, or tonsils to become chronically swollen [10].
  • Autoimmunity: The overactive immune system may begin to attack the body’s own healthy cells, such as those in the blood or the digestive tract [11].

The Practical and Emotional Impact

Living with a condition that is both an “underactive” and “overactive” immune disorder creates a heavy daily burden. It is not just about being “sick often”; it is about the constant management of a complex system.

  • Daily Disruptions: Recurrent infections and chronic fatigue can make it difficult to maintain regular attendance at school or work [12].
  • Physical Toll: Chronic inflammation in the lungs can lead to bronchiectasis, a condition where the airways become permanently widened and scarred, making it harder to clear mucus [10][13].
  • Emotional Weight: Families often report that the years spent without an answer were filled with anxiety and a sense of not being heard by the medical community [2]. Validating that your frustration is a normal response to an “ultra-rare” diagnosis is an important part of the healing process.

Understanding Your Specific Genetics

Your diagnosis was likely confirmed through genetic testing. APDS1 is an autosomal-dominant condition caused by a pathogenic or likely pathogenic heterozygous mutation, which means you only need one copy of the altered gene (from either parent, or occurring for the first time in you de novo) to have the disease [6]. Knowing your specific PIK3CD variant is crucial, as it helps your doctors distinguish APDS1 from other similar-looking immune disorders. Because of autosomal-dominant inheritance, there is a potential 50% transmission risk for an affected adult to pass it to their child. Genetic counseling is highly recommended for relatives and reproductive decisions [14][15]. Note that finding a “Variant of Uncertain Significance” (VUS) does not establish APDS1 on its own.

What This Diagnosis Does Not Mean

  • It is not contagious: You cannot “catch” APDS1.
  • It is not a fixed path: Symptom severity varies widely, even among family members with the same genetic variant. A diagnosis does not predict one inevitable course.

Common questions in this guide

What is APDS1?
APDS1 is a rare genetic immune disorder caused by a disease-causing change in the PIK3CD gene. It can weaken the body's ability to fight infections while also causing immune cells to become overactive and attack or inflame healthy tissue.
How is APDS1 inherited?
APDS1 follows an autosomal-dominant pattern, meaning one altered copy of PIK3CD can cause the condition. An affected adult has a 50% chance of passing the altered copy to each child, although the change can also arise for the first time in a person. Genetic counseling can help families understand these risks.
Why can APDS1 take years to diagnose?
Early APDS1 symptoms, especially repeated ear, sinus, or lung infections, can look like common childhood illnesses. Because APDS1 is ultra-rare, clinicians may not suspect it until infections become frequent or complications such as lung scarring develop; broader genetic testing can shorten the search.
How does APDS1 affect the immune system?
APDS1 can cause both immune deficiency and immune dysregulation. The immune deficiency may lead to recurrent infections and low protective antibodies, while immune dysregulation may cause enlarged lymph nodes, spleen, or tonsils and autoimmune problems.
What health checks may be needed after an APDS1 diagnosis?
A clinician may recommend baseline testing to look for existing lung damage and enlargement of organs such as the lymph nodes, spleen, or tonsils. The care team may also review the exact PIK3CD change, whether it is disease-causing, and whether family members need genetic counseling or testing.
Does a variant of uncertain significance confirm APDS1?
No. A variant of uncertain significance does not by itself establish an APDS1 diagnosis. Confirmation generally relies on a pathogenic or likely pathogenic PIK3CD variant together with the person's clinical findings.
Is APDS1 contagious, and does it predict exactly what will happen?
APDS1 is not contagious; it is caused by a genetic change and cannot be caught from another person. Its severity can vary widely, even among relatives with the same PIK3CD variant, so a diagnosis does not determine one fixed course.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Activated PI3K-delta syndrome 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was the exact PIK3CD variant identified, and is it considered 'pathogenic' or 'likely pathogenic'?
  2. 2.How long was the delay between my/my child's first symptoms and this diagnosis, and has that delay impacted my/their current lung health?
  3. 3.Given that this is an ultra-rare disease, how many other patients with APDS1 do you or this clinic currently manage?
  4. 4.How does the immune dysregulation (the overactivity) in my/my child's case compare to the immune deficiency (the underactivity)?
  5. 5.What baseline tests do we need now to check for existing lung damage or organ enlargement?

References

References (15)
  1. 1

    Case report on activated PI3K-delta syndrome.

    Crisanto-López IE, Pérez-Arzola AA, Hernández-Castañeda Y, et al.

    Boletin medico del Hospital Infantil de Mexico 2024; (81(4)):245-249 doi:10.24875/BMHIM.23000124.

    PMID: 39236673
  2. 2

    Diagnostic odyssey of patients with the rare immunodeficiency activated PI3 kinase delta syndrome (APDS): case study from expert and patient surveys.

    Wolf HM, Candotti F, Spelsberg R, et al.

    Frontiers in immunology 2026; (17()):1763482 doi:10.3389/fimmu.2026.1763482.

    PMID: 41859081
  3. 3

    A single center experience on PI3K/AKT/MTOR signaling defects: Towards pathogenicity assessment for four novel defects.

    Bildik HN, Esenboga S, Halaclı SO, et al.

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2024; (35(9)):e14245 doi:10.1111/pai.14245.

    PMID: 39312287
  4. 4

    Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.

    Maccari ME, Wolkewitz M, Schwab C, et al.

    The Journal of allergy and clinical immunology 2023; (152(4)):984-996.e10 doi:10.1016/j.jaci.2023.06.015.

    PMID: 37390899
  5. 5

    Clinical and immunological spectrum of five patients with activated phosphoinositide 3-kinase δ syndrome 1: A multicentric study from India.

    Bhattad S, Singh N, Mohite RS, et al.

    Journal of human immunity 2026; (2(4)):e20250251 doi:10.70962/jhi.20250251.

    PMID: 42169679
  6. 6

    Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives.

    IJspeert H, Dalm VASH, van Zelm MC, Edwards ESJ

    Immunotherapy advances 2024; (4(1)):ltae009 doi:10.1093/immadv/ltae009.

    PMID: 39679264
  7. 7

    Activated PI3Kδ syndrome type 2: Two patients, a novel mutation, and review of the literature.

    Olbrich P, Lorenz M, Cura Daball P, et al.

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2016; (27(6)):640-4 doi:10.1111/pai.12585.

    PMID: 27116393
  8. 8

    Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review.

    Jamee M, Moniri S, Zaki-Dizaji M, et al.

    Clinical reviews in allergy & immunology 2020; (59(3)):323-333 doi:10.1007/s12016-019-08738-9.

    PMID: 31111319
  9. 9

    Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence.

    Bloomfield M, Klocperk A, Zachova R, et al.

    Frontiers in pediatrics 2021; (9()):697706 doi:10.3389/fped.2021.697706.

    PMID: 34350147
  10. 10

    Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.

    Maccari ME, Abolhassani H, Aghamohammadi A, et al.

    Frontiers in immunology 2018; (9()):543 doi:10.3389/fimmu.2018.00543.

    PMID: 29599784
  11. 11

    Case Report: EBV Chronic Infection and Lymphoproliferation in Four APDS Patients: The Challenge of Proper Characterization, Therapy, and Follow-Up.

    Rivalta B, Amodio D, Milito C, et al.

    Frontiers in pediatrics 2021; (9()):703853 doi:10.3389/fped.2021.703853.

    PMID: 34540765
  12. 12

    A qualitative study to explore the burden of disease in activated phosphoinositide 3-kinase delta syndrome (APDS).

    Hitchcock I, Skrobanski H, Matter E, et al.

    Orphanet journal of rare diseases 2024; (19(1)):203 doi:10.1186/s13023-024-03215-9.

    PMID: 38760658
  13. 13

    Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.

    Condliffe AM, Chandra A

    Frontiers in immunology 2018; (9()):338 doi:10.3389/fimmu.2018.00338.

    PMID: 29556229
  14. 14

    Activated PI3Kδ syndrome in inborn errors of immunity: diagnostic strategies and clinical challenges.

    Bozkurt S, Ozturk N, Altunbas MY, et al.

    Frontiers in immunology 2025; (16()):1735023 doi:10.3389/fimmu.2025.1735023.

    PMID: 41583441
  15. 15

    Flow cytometry-based diagnostic approach for inborn errors of immunity: experience from Algeria.

    Tahiat A, Belbouab R, Yagoubi A, et al.

    Frontiers in immunology 2024; (15()):1402038 doi:10.3389/fimmu.2024.1402038.

    PMID: 39072316

This page is for informational purposes only and does not constitute medical advice. An immunologist and genetic counselor can interpret your APDS1 results and recommend appropriate testing for you or your child.